HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
NT-I7
NeoBase
NT2020
NT3020
NT4010
NT5010
PIPELINE
Clinical
R&D
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
Total
102
102
QUARTERLY UPDATE (Q3 2024)
2024-11-04
101
NeoImmuneTech Presents Promising Interim Results of CAR-T Combination with its NT-I7 Asset at ESMO 2024
2024-09-09
100
QUARTERLY UPDATE (Q2 2024)
2024-07-05
99
NeoImmuneTech Files International Patent Application for 'Multispecific Antibody Platform Technology'
2024-07-04
98
NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors in Immuno-Oncology
2024-06-04
97
EMA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome
2024-06-04
96
NeoImmuneTech’s Polish Subsidiary Obtains SME status
2024-05-30
95
Duke University Receives $6 Million contract from National Institutes of Health to Study NeoImmuneTech's NT-I7 in Treating Acute Radiation Syndrome
2024-05-13
94
NeoImmuneTech’s NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting
2024-04-18
93
QUARTERLY UPDATE (Q1 2024)
2024-04-04
1
2
3
4
5
>
>>
Search